Temporarily hold tirzepatide and add prochlorperazine or metoclopramide as second-line antiemetics
The next step is to temporarily discontinue tirzepatide and escalate antiemetic therapy with prochlorperazine (10 mg IV q6h) or metoclopramide as second-line agents, while continuing IV hydration and monitoring for metabolic complications including euglycemic ketoacidosis.
Immediate Management
Since the patient has failed first-line ondansetron (Zofran) therapy after 12 hours of persistent vomiting, you need to escalate antiemetic management while addressing the underlying drug-induced cause:
Antiemetic Escalation
- Add prochlorperazine 10 mg IV q6h as a second-line agent 1, 2
- Alternatively, use metoclopramide as a third-line dopamine antagonist 1, 2
- Consider adding lorazepam 0.5-2 mg IV q6h PRN for anxiety-related nausea component 2
- The guideline evidence supports using agents from different drug classes when first-line 5-HT3 antagonists fail 3, 2
Critical: Hold Tirzepatide
Temporarily discontinue tirzepatide immediately 1. The 2025 expert consensus on treatment-emergent adverse events recommends holding causative therapy when symptomatic measures fail for moderate-to-severe vomiting (defined as inability to keep food down and dehydration) 1. This patient meets criteria with 12 hours of vomiting, dehydration requiring IV fluids, and inadequate oral intake.
Metabolic Monitoring
Screen for euglycemic ketoacidosis urgently - this is a critical pitfall with tirzepatide in non-diabetic patients:
- Check serum ketones, venous blood gas, anion gap, and glucose immediately 4, 5, 6
- Recent 2026 case reports document multiple instances of tirzepatide-induced starvation ketoacidosis in non-diabetic patients presenting with persistent vomiting and poor intake 4, 5, 6, 7
- These patients developed severe high-anion gap metabolic acidosis (pH as low as 6.96-7.22) despite normal or only mildly elevated glucose 4, 5, 8
- If ketoacidosis is present: initiate 10% dextrose-containing IV fluids (not just saline), thiamine, and electrolyte replacement 5
Additional Supportive Measures
- Ensure adequate hydration: Continue IV crystalloid with dextrose-containing fluids given risk of starvation ketoacidosis 5
- Check and correct electrolytes: Hypokalemia and hypomagnesemia can worsen outcomes and prolong QT interval (relevant given ondansetron use) 9
- Consider adding H2-blocker or proton pump inhibitor if not already given, as patients may have difficulty discriminating gastroesophageal reflux from nausea 2, 10
Common Pitfalls to Avoid
- Do not simply repeat ondansetron - the patient has already failed this agent; you need a different mechanism of action 2
- Do not miss euglycemic ketoacidosis - normal glucose does NOT exclude ketoacidosis in tirzepatide users 4, 5, 6
- Do not continue tirzepatide - persistent vomiting with inability to maintain oral intake mandates temporary drug discontinuation 1
- Do not use oral medications - the patient cannot keep anything down; use IV or rectal routes 2
Disposition and Follow-up
- Admit for observation if metabolic acidosis present or if vomiting persists despite escalated therapy
- Plan to restart tirzepatide at reduced dose (e.g., 2.5 mg weekly) only after complete resolution of symptoms and adequate oral intake is established 1
- Consider permanent discontinuation if severe vomiting recurs with rechallenge 1
- Educate patient about early warning signs of ketoacidosis and importance of maintaining caloric intake while on tirzepatide 4, 5
The evidence strongly supports that tirzepatide-induced nausea/vomiting with dehydration represents a treatment-emergent adverse event requiring both symptomatic management with escalated antiemetics AND temporary drug discontinuation 1. The recent surge in case reports of tirzepatide-associated ketoacidosis in non-diabetic patients (2025-2026) makes metabolic screening mandatory in this clinical scenario 4, 5, 6, 7.